These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 8040121)
1. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on aspergillosis virulence and toxicity of liposomal amphotericin B in mice. Moonis M; Ahmad I; Bachhawat BK J Antimicrob Chemother; 1994 Mar; 33(3):571-83. PubMed ID: 8040121 [TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855 [TBL] [Abstract][Full Text] [Related]
3. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis. Ahmad I; Sarkar AK; Bachhawat BK Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):85-90. PubMed ID: 2695834 [TBL] [Abstract][Full Text] [Related]
4. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B. Ahmad I; Sarkar AK; Bachhawat BK Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711 [TBL] [Abstract][Full Text] [Related]
5. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies. Chakraborty KK; Naik SR Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574 [TBL] [Abstract][Full Text] [Related]
7. Liposome-encapsulated amphotericin B in the treatment of experimental murine candidiasis. Miyazaki T; Kohno S; Kaku M; Koga H; Yamaguchi K Tohoku J Exp Med; 1990 Aug; 161(4):273-81. PubMed ID: 2256101 [TBL] [Abstract][Full Text] [Related]
8. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
9. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis. Saxena S; Khan JA; Ghosh PC J Antimicrob Chemother; 1998 Nov; 42(5):635-42. PubMed ID: 9848448 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins. Chakraborty KK; Naik SR J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624 [TBL] [Abstract][Full Text] [Related]
12. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin. Moonis M; Ahmad I; Bachhawat BK Indian J Biochem Biophys; 1992 Aug; 29(4):339-45. PubMed ID: 1427960 [TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin-B as a therapeutic measure to control experimental aspergillosis in BALB/c mice. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1990 Dec; 27(6):370-4. PubMed ID: 2102483 [No Abstract] [Full Text] [Related]
15. Changes in murine bone marrow macrophages and erythroid burst-forming cells following the intravenous injection of liposome-encapsulated dichloromethylene diphosphonate (Cl2MDP). Giuliani AL; Wiener E; Lee MJ; Brown IN; Berti G; Wickramasinghe SN Eur J Haematol; 2001 Apr; 66(4):221-9. PubMed ID: 11380601 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. Allen SD; Sorensen KN; Nejdl MJ; Durrant C; Proffit RT J Antimicrob Chemother; 1994 Dec; 34(6):1001-13. PubMed ID: 7730214 [TBL] [Abstract][Full Text] [Related]
17. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. van Rooijen N; van Nieuwmegen R Cell Tissue Res; 1984; 238(2):355-8. PubMed ID: 6239690 [TBL] [Abstract][Full Text] [Related]
18. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Szoka FC; Milholland D; Barza M Antimicrob Agents Chemother; 1987 Mar; 31(3):421-9. PubMed ID: 3579259 [TBL] [Abstract][Full Text] [Related]
19. Repopulation of murine Kupffer cells after intravenous administration of liposome-encapsulated dichloromethylene diphosphonate. Yamamoto T; Naito M; Moriyama H; Umezu H; Matsuo H; Kiwada H; Arakawa M Am J Pathol; 1996 Oct; 149(4):1271-86. PubMed ID: 8863675 [TBL] [Abstract][Full Text] [Related]
20. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. van Etten EW; Otte-Lambillion M; van Vianen W; ten Kate MT; Bakker-Woudenberg AJ J Antimicrob Chemother; 1995 Apr; 35(4):509-19. PubMed ID: 7628985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]